

## Declaration of Interests Register

**Technology Appraisal Committee A**

**Publication Date: 17/06/2020**

**Topic: Ustekinumab for treating moderately to severely active ulcerative colitis [TA633]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Mr Adrian Griffin	Committee member	Direct Financial	Employed by Johnson & Johnson (Janssen is part of J&J company)	25/02/2020	25/02/2020	-	Did not participate in the appraisal. Agreed by Chair Dr Jane Adam
Dr Richard Pollock	Clinical Expert	Direct, non financial	South London Clinical Research Network specialist Lead for Gastroenterology and a Committee member for the British Society of Gastroenterology IBD section	25/02/2020	25/02/2020	-	Declaration made and participated in the appraisal Agreed by Chair Dr Jane Adam
Dr Peter Irving	Clinical Expert	Direct financial	Honoraria for speaking on behalf of, or acting in an advisory capacity for companies related to this appraisal and others including Janssen, Pfizer, Roche, Genentech,	25/02/2020	25/02/2020	-	Declaration made and participated in the appraisal Agreed by Chair Dr Jane Adam

			Abbvie, MSD, Sandoz, Falk, Ferring, Tillots, Arena, Gilead, Takeda and Lilly,				
--	--	--	--	--	--	--	--

Link to Committee A interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-A-interests-register.pdf>

#### GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.